Influence of single and multiple doses of amifostine on the efficacy and the pharmacokinetics of carboplatin in mice

British Journal of Cancer

Volumn 75, Issue 10, 1997, Pages 1439-1446

  Korst, A E C ^a   Boven, E ^a   Van Der Sterre, M L T ^a   Fichtinger Schepman, A M J ^b   Van Der Vijgh, W J F ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

Author keywords

Amifostine; Anti tumour activity; Carboplatin; Hypothermia; Pharmacokinetics; Platinum DNA adduct

Indexed keywords

AMIFOSTINE; CARBOPLATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BODY TEMPERATURE; CONTROLLED STUDY; DNA ADDUCT; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG LIVER LEVEL; DRUG POTENTIATION; FEMALE; HYPOTHERMIA; INTRAPERITONEAL DRUG ADMINISTRATION; KIDNEY; NONHUMAN; NUDE MOUSE; OVARY CANCER; PRIORITY JOURNAL; XENOGRAFT;

EID: 0030909582     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.247     Document Type: Article

References (26)

1. Betticher DC, Anderson H, Ranson M and Thatcher N (1995) Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small cell lung cancer. Br J Cancer 72: 1551-1555
2. Blommaert FA, Van Dijk-Knijnenburg HCM, Dijt FJ, Den Engelse L, Baan R, Berends F and Fichtinger-Schepman AMJ (1995) Formation of DNA adducts by the anticancer drug carhoplatin: different nucleotide sequence preferences in vitro and in cells. Biochemistry 34: 8474-8480
3. Boven E, van der Vijgh WJF, Nauta MM, Schlüper HMM and Pinedo HM (1985) Comparative activity and distribution studies of five platinum analogues in nude mice bearing human ovarian carcinoma xenografts. Cancer Res 45: 86-90
4. Brown DQ, Graham WJ, Mackenzie LJ, Pittock JW and Shaw LM (1988) Can WR-2721 be improved upon? Pharmacol Ther 39: 157-168
5. Calabro-Jones PM, Aguilera JA, Ward JF, Smoluk GD and Fahey RC (1988) Uptake of WR-2721 derivatives by cells in culture: identification of the transported form of the drug. Cancer Res 48: 3634-3640
6. Cappizi RL (1994) Protection of normal tissues from the cytotoxic effects of chemotherapy by amifostine (ethyol): clinical experiences. Semin Oncol 21: 8-15
7. Fichtinger-Schepman AMJ, Van Oosterom AT, Lohman PHM and Berends F (1987) Cis-diamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: Quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum(II). Cancer Res 47: 3000-3004
8. Millar JL, McElwain TJ and Clutterbuck RD (1982) The modification of melphalan toxicity in tumor bearing mice by S-2-(3-aminopropylamino)ethylphosphorothioic acid (WR 2721). Am J Clin Oncol 5: 321-328
9. Page RL, Thrall DE, Dewhirst MW and Meyer RE (1987) Whole body hyperthermia: rationale and potential use for cancer treatment. J Vet Int Med 1: 110-120
10. Paine GD, Taylor CW, Lopez MHA, Johnson CS and Capizzi RL (1996) Effects of amifostine and paclitaxel on growth of human ovarian carcinoma xenografts in the severe combined immune-deficient mouse: preliminary results. Semin Oncol 23 (suppl. 8): 35-39
11. 32P-postlabeling analysis of benzo(a)pyrene-DNA adducts formed in vitro upon activation of benzo(a)pyrene by human, rabbit and rodent liver microsomes. Carcinogenesis 14: 1945-1950
12. Schiller JH, Storer B, Berlin J, Wittenkeller J, Larson M, Pharo L, Larson M and Berry W (1996) Amifostine, cisplatin and vinblastine in metastatic non-small cell lung cancer: a report of high response rates and prolonged survival. J Clin Oncol 14: 1913-1921
13. Shaw LM, Glover D, Turrisi A, Brown DQ, Bonner HS, Norfleet AL, Weiler C, Glick JH and Kligerman MM (1988) Pharmacokinetics of WR-2721. Pharmacol Ther 39: 195-201
14. Shaw LM, Bonner HS and Brown DQ (1994) Metabolic pathways of WR-2721 (ethyol, amifostine) in the Balb/c mouse. Drug Metab Dispos 22: 895-902
15. Treskes M, Holwerda U, Klein I, Pinedo HM and Van der Vijgh WJF (1991) The chemical reactivity of the modulating agent WR 2721 (ethiofos) and its metabolites with the antitumor agents cisplatin and carboplatin. Biochem Pharmacol 42: 2125-2130
16. Treskes M, Boven E, Holwerda C, Pinedo HM and Van der Vijgh WJF (1992a) Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR-2721 in the mouse. Cancer Res 52: 2257-2260
17. Treskes M, Nijtmans LG, Fichtinger-Schepman AMJ and Van der Vijgh WJF (1992b) Effects of the modulating agent WR2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro in comparison to the effects of thiosulphate and diethylthiocarbamate. Biochem Pharmacol 43: 1013-1019
18. Treskes M, Boven E, Van de Loosdrecht AA, Wijffels JFAM, Cloos J, Peters GJ, Pinedo HM and Van der Vijgh WJF (1994) Effects of the modulating agent WR2721 on myelotoxicity and antitumour activity in carboplatin-treated mice. Eur J Cancer 30A: 183-187
19. Twentyman PR (1983) Modification by WR-2721 of the response to chemotherapy of tumours and normal tissues in the mouse. Br J Cancer 47: 57-63
20. Utley JF, Seaver N, Newton GL and Faney RC (1984) Pharmacokinetics of WR-1065 in mouse tissue following treatment with WR-2721. Int J Radiat Oncol Biol Phys 10: 1525-1528
21. Valeriote F and Tolen S (1982) Protection and potentiation of nitrogen mustard cytotoxicity by WR-2721. Cancer Res 42: 4330-4331
22. Van der Vijgh WJF (1991) Clinical pharmacokinetics of carboplatin. Clin Pharmacokin 21: 242-261
23. van der Vijgh WJF and Peters GJ (1994) Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (Ethyol): Preclinical aspects. Semin Oncol 21: 2-7
24. Van Der Wilt CL, Van Laar JAM, Gyergyay F, Smid K and Peters GJ (1992) Biochemical modification of the toxicity and antitumor effect of 5-fluorouracil and cisplatinum by WR-2721 in mice. Eur J Cancer 28A: 2017-2024.
25. Vermorken JB, Punt CJA, Eeltink CM, Van Maanen L, Korst AEC, Oster W, Kwakkelstein MO and Van der Vijgh WJF (1995) Phase I trial of carboplatin and amifostine (WR-2721). Proc AACR 36: 240
26. Yuhas JM (1980) Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)ethyl-phosphorothioic acid. Cancer Res 40: 1514-1524